Liu Gui, Markowitz Lauri E, Hariri Susan, Panicker Gitika, Unger Elizabeth R
Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
J Infect Dis. 2016 Jan 15;213(2):191-8. doi: 10.1093/infdis/jiv403. Epub 2015 Aug 27.
A 9-valent human papillomavirus (HPV) vaccine, licensed in 2014, prevents 4 HPV types targeted by the quadrivalent vaccine (6/11/16/18) and 5 additional high-risk (HR) types (31/33/45/52/58). Measuring seropositivity before vaccine introduction provides baseline data on exposure to types targeted by vaccines.
We determined seroprevalence of HPV 6/11/16/18/31/33/45/52/58 among 4943 persons aged 14-59 years who participated in the National Health and Nutrition Examination Survey, 2005-2006.
Among females, seroprevalence was 40.5% for any of the 9 vaccine types, 30.0% for any 7 HR types (16/18/31/33/45/52/58), 19.0% for any 5 additional types (31/33/45/52/58), and 18.3% for 16/18. Compared with non-Hispanic whites, non-Hispanic blacks had higher seroprevalence of 31/33/45/52/58 (36.8% vs 15.9%) and 16/18 (30.1% vs 17.8%), while Mexican Americans had higher seroprevalence of 31/33/45/52/58 (23.6% vs 15.9%) (P < .05 for all). In multivariable analyses of data from females, race/ethnicity, number of sex partners, and age were associated with 16/18 and 31/33/45/52/58 seropositivity. Seropositivity was lower among males than among females (P < .001 for all type categories).
In 2005-2006, about 40% of females and 20% of males had serological evidence of exposure to ≥1 of 9 HPV types. Seroprevalence of all type categories, especially HPV 31/33/45/52/58 among females, varied by race/ethnicity.
一种9价人乳头瘤病毒（HPV）疫苗于2014年获得许可，可预防4种四价疫苗所针对的HPV类型（6/11/16/18）以及另外5种高危（HR）类型（31/33/45/52/58）。在引入疫苗之前测量血清阳性率可提供有关疫苗所针对类型暴露情况的基线数据。
我们在参加2005 - 2006年国家健康与营养检查调查的4943名14至59岁人群中确定了HPV 6/11/16/18/31/33/45/52/58的血清流行率。
在女性中，9种疫苗类型中任何一种的血清流行率为40.5%，7种HR类型（16/18/31/33/45/52/58）中任何一种的血清流行率为30.0%，另外5种类型（31/33/45/52/58）中任何一种的血清流行率为19.0%，16/18的血清流行率为18.3%。与非西班牙裔白人相比，非西班牙裔黑人31/33/45/52/58（36.8%对15.9%）和16/18（30.1%对17.8%）的血清流行率更高，而墨西哥裔美国人31/33/45/52/58（23.6%对15.9%）的血清流行率更高（所有比较P <.05）。在对女性数据的多变量分析中，种族/族裔、性伴侣数量和年龄与16/18以及31/33/45/52/58血清阳性率相关。男性的血清阳性率低于女性（所有类型类别P <.001）。
在2005 - 2006年，约40%的女性和20%的男性有血清学证据表明暴露于9种HPV类型中的至少1种。所有类型类别的血清流行率，尤其是女性中HPV 31/33/45/52/58的血清流行率，因种族/族裔而异。
